GlassScriptPhysician profile
Lisa Phuong
NPI 1265826234
$3,668.99
in general payments reported to CMS, 2019-2025
41 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $520 · 2023: $821 · 2024: $892 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.27 | 2021-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $296.85 | 2022-2025 | |
| Celgene Corporation | $230.58 | 2022-2025 | Reblozyl, Pomalyst, Abecma |
| Gilead Sciences, INC. | $201.83 | 2022-2025 | Trodelvy |
| Genentech USA, INC. | $197.59 | 2022-2025 | Phesgo, Tecentriq, Perjeta |
| Amgen INC. | $164.25 | 2021-2023 | Kyprolis, Lumakras |
| Incyte Corporation | $161.78 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $144.40 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $142.97 | 2023-2025 | Libtayo |
| Seagen INC. | $140.09 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $131.80 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Janssen Biotech, INC. | $113.89 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $93.17 | 2021-2024 | Opdivo |
| Abbvie INC. | $82.95 | 2021 | |
| Genzyme Corporation | $81.24 | 2021-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $78.00 | 2023-2025 | |
| Emd Serono, INC. | $77.35 | 2022-2023 | Bavencio |
| Mirati Therapeutics, INC. | $72.78 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $71.36 | 2024-2025 | |
| Pfizer INC. | $64.74 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.67 | 2023-2025 | Ninlaro, Alunbrig |
| Astellas Pharma US INC | $63.23 | 2023-2025 | Padcev, Vyloy |
| Glaxosmithkline, LLC. | $54.48 | 2023-2024 | Ojjaara, Shingrix |
| Exelixis INC. | $53.30 | 2024-2025 | Cabometyx |
| Array Biopharma INC | $52.92 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Stemline Therapeutics INC. | $50.38 | 2024-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $47.73 | 2022-2025 | |
| Lilly USA, LLC | $44.05 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $43.48 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $40.09 | 2024-2025 | Keytruda |
| Coherus Oncology, INC. | $39.07 | 2023-2025 | Loqtorzi |
| Aveo Pharmaceuticals, INC. | $31.06 | 2024-2025 | |
| Geron Corporation | $27.65 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $25.15 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $24.16 | 2022 | |
| Daiichi Sankyo INC. | $22.94 | 2025 | Enhertu |
| Taiho Oncology, INC. | $20.53 | 2025 | |
| Karyopharm Therapeutics INC. | $18.18 | 2024 | Xpovio |
| Pharmaessentia USA Corporation | $18.05 | 2023 | Besremi |
| Puma Biotechnology, INC. | $15.98 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Phuong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.